Trial Type
Follow-Up Treatment (Metastatic Disease)
Description for experts
A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
Description for laymen
A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design
JSON Data
{
"short_title": "XPORT",
"data_mode": "900",
"data_mode_number": "000002432",
"official_title": "A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "gtThird",
"ctgov_number": "NCT0561193",
"eudract_number": null,
"general_contact_email": "studiensekretariat.gyn@ukdd.de",
"general_contact_phone": "+49 351-4584202",
"hauptpruefer_dd_name": "Prof. Dr. med. Pauline Wimberger",
"description_laie_de": "Eine randomisierte, placebokontrollierte, doppelblinde, multizentrische Phase-III-Studie mit Selinexor in der Erhaltungstherapie nach systemischer Therapie bei Patientinnen mit p53-Wildtyp, fortgeschrittenem oder rezidiviertem Endometriumkarzinom: Begr\u00fcndung, Methoden und Studiendesign",
"description_laie_en": "A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design",
"description_expert_de": "Eine randomisierte, placebokontrollierte, doppelblinde, multizentrische Phase-III-Studie mit Selinexor in der Erhaltungstherapie nach systemischer Therapie bei Patientinnen mit p53-Wildtyp, fortgeschrittenem oder rezidiviertem Endometriumkarzinom: Begr\u00fcndung, Methoden und Studiendesign",
"description_expert_en": "A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "III",
"main_cat_id": 3,
"sub_cat_id": 20
}
